X
Pfizer eyes gastro use for Xeljanz after thumbs-up from FDA advisers
https://pharmaphorum.com/news/pfizer-eyes-gastro-use-xeljanz-thumbs-fda-advisers/
gastrointestinal
EU approval for Crohn’s another boost for fast-growing Stelara
J&J unit’s blockbuster gets new use.
Alkermes closing in on Biogen with MS rival
ALKS 8700 may have fewer side effects than Tecfidera.
AZ sells potential Crohn’s drug to Allergan
Amgen gets share of $1.5 billion deal
Biogen takes on Tecfidera adherence issues
Company hopes to coach patients with stomach side-effects.
Celgene baffles market with Crohn’s drug data
Analysts left guessing from snippet of early phase data.
Shire buys rights to Pfizer gastrointestinal drug
Shire has bought rights to PF-00547659 for an undisclosed sum.
Biosimilar switching not suitable for all patients
Antibodies against originator will also target biosimilar.
